Do "elderly fit" patients have less comorbidity?

International Journal of Radiation Oncology Biology Physics

Volumn 55, Issue 5, 2003, Pages 1166-1168

  Firat, Selim ^a   Gore, Elizabeth ^a   Byhardt, Roger W ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN DERIVATIVE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER PREVENTION; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; EDITORIAL; HEART INFARCTION; HUMAN; HYPERTENSION; LUNG CANCER; LUNG NON SMALL CELL CANCER; ONCOLOGY; PERFORMANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SKULL IRRADIATION; UNSTABLE ANGINA PECTORIS; WEIGHT REDUCTION;

EID: 0037376964     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)04577-7     Document Type: Editorial

References (26)

1. Ludbrook JJS, Truong PT, Macneil MV, et al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small cell lung cancer? A community-based population analysis. Int J Radiat Oncol Biol Phys 2003;55:1321-1330.
2. Dajczman E., Fu L.Y., Small D., et al. Treatment of small cell lung carcinoma in the elderly. Cancer. 77:1996;2032-2038.
3. Langer C.J., Manola J., Bernardo P., et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer. Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 94:2002;173-181.
4. Langer C.J., Hsu C., Curran W., et al. Do elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy? A secondary analysis of RTOG 94-10 (abstract). Int J Radiat Oncol Biol Phys. 51:2001;31.
5. Evans W.K., Radwi A., Tomiak E., et al. Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer. Am J Clin Oncol. 18:1995;149-155.
6. Effects of Vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 91:1999;66-72.
7. Hutchins L.F., Unger J.M., Crowley J.J., et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 341:1999;2061-2067.
8. Trimble EL, Carter CL, Cain D, et al. Representation of older patients in cancer treatment trials. Cancer 1994;74:2208-2214.
9. Werner-Wasik M., Scott C., Cox J.D., et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group patients with locally-advanced non-small-cell lung cancer Identification of five groups with different survival. Int J Radiat Oncol Biol Phys. 48:2000;1475-1482.
10. Firat S., Bousamra M., Gore E., et al. Comorbidity and KPS are independent prognostic factors in stage I non-small cell lung cancer. Int J Radiat Biol Phys. 52:2002;1047-1057.
11. Hall H.I., Satariano W.A., Thompson T., et al. Initial treatment for prostate carcinoma in relation to comorbidity and symptoms. Cancer. 95:2002;2308-2315.
12. Greenfield S., Blanco D.M., Elashoff R.M., et al. Patterns of care related to age of breast cancer patients. JAMA. 257:1987;2766-2770.
13. Kornblith A.B., Kemeny M., Peterson B.L., et al. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer. 95:2002;989-996.
14. Extermann M., Overcash J., Lyman G.H., et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 16:1998;1582-1587.
15. Firat S., Byhardt R.W., Gore E. Comorbidity and Karnofsky performance score are independent prognostic factors in stage III non-small-cell lung cancer. An institutional analysis of patients treated on four RTOG studies. Int J Radiat Biol Phys. 54:2002;357-364.
16. Pugliano F.A., Piccirillo J.F., Zequeira M.R., et al. Clinical severity staging system for oropharyngeal cancer. Arch Otolaryngol Head Neck Surg. 123:1997;1118-1124.
17. Piccirillo J.F., Feinstein A.R. Clinical symptoms and comorbidity Significance for the prognostic classification of cancer. Cancer. 77:1996;834-842.
18. Feinstein A.r, Schrimpff C.R., Andrews J.F. Jr, et al. Cancer of the larynx. J Chronic Dis. 30:1977;277-305.
19. Wells C.K., Stoller J.K., Feinstein A.R., et al. Comorbid and clinical determinants of prognosis in endometrial cancer. Arch Intern Med. 144:1984;2004-2009.
20. Clemens J.D., Feinstein A.R., Holabird N., et al. A new clinical-anatomic staging system for evaluating prognosis and treatment of prostatic cancer. J Chronic Dis. 39:1986;913-928.
21. Piccirillo J.F., Wells C.K., Sasaki C.T., et al. New clinical severity staging system for cancer of the larynx. Ann Otol Rhinol Laryngol. 103:1994;83-92.
22. Feinstein A.R., Wells C.K. A clinical-severity staging system for patients with lung cancer. Medicine. 69:1990;1-33.
23. Satariano W.A., Ragland D.R. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 120:1994;104-110.
24. Singh B., Bhaya M., Stern J., et al. Validation of the Charlson Comorbidity Index in patients with head and neck cancer A multi-institutional study. Laryngoscope. 107:1997;1469-1475.
25. Singh B., Bhaya M., Zimbler M., et al. Impact of comorbidity on outcome of young patients with head and neck squamous cell carcinoma. Head Neck. 20:1998;1-7.
26. Frasci G., Lorusso B., Panza N. Gemcitabine plus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 18:2000;2529-2536.